Ferucarbotran

Drug Profile

Ferucarbotran

Alternative Names: BAY 864884; Cliavist; Ferrixan; Resovist; SHU 555A; ZK 132281

Latest Information Update: 24 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer Yakuhin; Meito Sangyo
  • Class Heavy metals; Oxides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Liver cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 24 Sep 2013 Discontinued - Preregistration for Liver cancer (diagnosis) in USA (IV)
  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top